Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial

易普利姆玛 医学 转移性黑色素瘤 内科学 双盲 肿瘤科 黑色素瘤 癌症 免疫疗法 病理 安慰剂 替代医学 癌症研究
作者
Paolo A. Ascierto,Michele Del Vecchio,Caroline Robert,Andrzej Adam Mackiewicz,Vanna Chiarion‐Sileni,Ana Maria Arance,Célèste Lebbé,Lars Bastholt,Omid Hamid,Piotr Lukasz Rutkowski,Catriona M. McNeil,Claus Garbe,Carmen Loquai,Brigitte Dréno,Luc Thomas,Jean‐Jacques Grob,Gabriella Liszkay,Marta Nyakas,Ralf Gutzmer,Joanna Pikiel
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:18 (5): 611-622 被引量:544
标识
DOI:10.1016/s1470-2045(17)30231-0
摘要

Summary

Background

A phase 2 trial suggested increased overall survival and increased incidence of treatment-related grade 3–4 adverse events with ipilimumab 10 mg/kg compared with ipilimumab 3 mg/kg in patients with advanced melanoma. We report a phase 3 trial comparing the benefit–risk profile of ipilimumab 10 mg/kg versus 3 mg/kg.

Methods

This randomised, double-blind, multicentre, phase 3 trial was done in 87 centres in 21 countries worldwide. Patients with untreated or previously treated unresectable stage III or IV melanoma, without previous treatment with BRAF inhibitors or immune checkpoint inhibitors, were randomly assigned (1:1) with an interactive voice response system by the permuted block method using block size 4 to ipilimumab 10 mg/kg or 3 mg/kg, administered by intravenous infusion for 90 min every 3 weeks for four doses. Patients were stratified by metastasis stage, previous treatment for metastatic melanoma, and Eastern Cooperative Oncology Group performance status. The patients, investigators, and site staff were masked to treatment assignment. The primary endpoint was overall survival in the intention-to-treat population and safety was assessed in all patients who received at least one dose of study treatment. This study is completed and was registered with ClinicalTrials.gov, number NCT01515189.

Findings

Between Feb 29, and July 9, 2012, 727 patients were enrolled and randomly assigned to ipilimumab 10 mg/kg (365 patients; 364 treated) or ipilimumab 3 mg/kg (362 patients; all treated). Median follow-up was 14·5 months (IQR 4·6–42·3) for the ipilimumab 10 mg/kg group and 11·2 months (4·9–29·4) for the ipilimumab 3 mg/kg group. Median overall survival was 15·7 months (95% CI 11·6–17·8) for ipilimumab 10 mg/kg compared with 11·5 months (9·9–13·3) for ipilimumab 3 mg/kg (hazard ratio 0·84, 95% CI 0·70–0·99; p=0·04). The most common grade 3–4 treatment-related adverse events were diarrhoea (37 [10%] of 364 patients in the 10 mg/kg group vs 21 [6%] of 362 patients in the 3 mg/kg group), colitis (19 [5%] vs nine [2%]), increased alanine aminotransferase (12 [3%] vs two [1%]), and hypophysitis (ten [3%] vs seven [2%]). Treatment-related serious adverse events were reported in 133 (37%) patients in the 10 mg/kg group and 66 (18%) patients in the 3 mg/kg group; four (1%) versus two (<1%) patients died from treatment-related adverse events.

Interpretation

In patients with advanced melanoma, ipilimumab 10 mg/kg resulted in significantly longer overall survival than did ipilimumab 3 mg/kg, but with increased treatment-related adverse events. Although the treatment landscape for advanced melanoma has changed since this study was initiated, the clinical use of ipilimumab in refractory patients with unmet medical needs could warrant further assessment.

Funding

Bristol-Myers Squibb.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
忧郁的莫茗完成签到,获得积分10
2秒前
小橘完成签到,获得积分10
4秒前
李爱国的应助被科研不是科幻采纳,获得10
4秒前
4秒前
5秒前
enkidu发布了新的文献求助10
5秒前
也未可知完成签到 ,获得积分0
5秒前
5秒前
丹丹完成签到 ,获得积分10
5秒前
yian007发布了新的文献求助10
6秒前
香辣牛排发布了新的文献求助10
6秒前
6秒前
孔之如冬完成签到 ,获得积分10
6秒前
6秒前
7秒前
chan完成签到,获得积分10
7秒前
秋风的应助被郦稀采纳,获得10
7秒前
杨青黄发布了新的文献求助10
8秒前
9秒前
mhx1234567890完成签到,获得积分20
9秒前
cjr发布了新的文献求助10
9秒前
xiejie发布了新的文献求助10
9秒前
科烟生完成签到,获得积分10
9秒前
10秒前
所所的应助被果粒橙采纳,获得10
10秒前
10秒前
huang完成签到,获得积分10
11秒前
小羊发布了新的文献求助10
12秒前
Gilhog完成签到,获得积分10
12秒前
小蘑菇的应助被PhDL1采纳,获得10
12秒前
光亮绮山完成签到,获得积分10
12秒前
Nothing完成签到,获得积分10
13秒前
14秒前
14秒前
14秒前
14秒前
3475发布了新的文献求助10
15秒前
树枝完成签到 ,获得积分10
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8178807
求助须知:如何正确求助?哪些是违规求助? 9569558
关于积分的说明 21805222
捐赠科研通 7773974
什么是DOI,文献DOI怎么找? 3432933
关于科研通互助平台的介绍 2556873
邀请新用户注册赠送积分活动 2478593